Jazz Pharmaceuticals Unveils New Data on Xywav Treatment for Narcolepsy at SLEEP 2025 Conference

Jazz Pharmaceuticals Presents Groundbreaking Data on Xywav for Narcolepsy at SLEEP 2025



On June 9, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) made headlines at the SLEEP 2025 conference by unveiling late-breaking Phase 4 data that highlights the treatment advantages of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in individuals suffering from narcolepsy. This presentation marked a significant step forward in understanding how low-sodium oxybate can improve the lives of those with narcolepsy, a condition that is often accompanied by serious health risks.

Among the key studies presented was the Phase 4 XYLO switch trial, which indicated that patients switching from a higher-sodium oxybate regimen to the low-sodium formulation of Xywav saw notable reductions in mean 24-hour ambulatory systolic blood pressure. Specifically, participants experienced a statistically significant decrease in blood pressure of −4.1 mmHg (P=0.0019) over six weeks. This change underscores the importance of sodium intake management in patients with narcolepsy, as they are more susceptible to cardiovascular diseases.

Dr. Richard J. Kovacs, Chief Medical Officer of the American College of Cardiology, noted, "People living with narcolepsy face a heightened risk of cardiovascular complications. Monitoring cardiovascular indicators and minimizing excess sodium intake in these patients is paramount. The XYLO study's findings further our commitment to improving the health outcomes of those affected."

A secondary analysis within the DUET trial cohort also shed light on the effectiveness of Xywav. This analysis involved adults who were prescribed dosages of 9-12 grams per night. Results showed a significant reduction in excessive daytime sleepiness (EDS) based on the Epworth Sleepiness Scale, with participants reporting improved scores after dose optimization. The average prescribed dosage for patients during the study was determined to be 11.2g/night, higher than the standard range, which emphasizes the necessity for personalized treatment.

The findings from both studies reinforce the established profile of Xywav as a well-tolerated treatment—32.8% of participants reported treatment-emergent adverse events (TEAEs), with most being mild or moderate in severity, consistent with previously understood safety profiles.

Narcolepsy is recognized as a chronic neurological disorder characterized by disrupted nighttime sleep and profound daytime sleepiness, along with potential risks of cataplexy—sudden muscle weakness triggered by strong emotions. The condition significantly impacts patients' social, psychological, and professional lives and is a risk factor for numerous health complications, extending to hypertension and cardiovascular diseases.

Xywav's formulation is distinct from traditional sodium oxybate medications, as it contains 92% less sodium. At its maximum recommended dosage, Xywav delivers only about 131 mg of sodium as opposed to over 1600 mg from other treatments. This reduction is crucial in a patient population already burdened by health complications.

Kelvin Tan, the Chief Medical Affairs Officer at Jazz Pharmaceuticals, elaborated, "Our findings demonstrate the ability of Xywav to mitigate the sodium burden, which is a modifiable risk factor for cardiovascular conditions in these patients. It's essential for healthcare providers to advocate low-sodium treatment options to enhance patient outcomes."

Pharmaceutical innovations like Xywav have the potential to relieve the psychological and physical burden placed on individuals with narcolepsy. With no known cure for this debilitating disorder, effective management is critical. The research showcased at SLEEP 2025 adds to the compelling evidence for prescribing lower-sodium treatments to help reduce associated health risks and improve quality of life.

As the medical community continues to learn more about the implications of narcolepsy and the various treatment avenues available, updates from clinical trials such as those conducted by Jazz Pharmaceuticals may well play an instrumental role in shaping future therapeutic strategies.

For more comprehensive insights, all presented abstracts can be accessed online at sleepmeeting.org/abstract-supplements.

About Jazz Pharmaceuticals


Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on innovating to transform patient lives. With a diverse portfolio that includes significant therapies for sleep disorders, Jazz is dedicated to addressing unmet medical needs. For additional information, visit www.jazzpharmaceuticals.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.